The drug at the center of the study, AZD1390, is an orally available, brain-penetrant inhibitor of ATM kinase, a protein best known to biologists for its role in sensing and repairing damaged DNA. The Duke team, however, was interested in a different job for the molecule: blocking ferroptosis, an iron-dependent form of regulated cell death driven by the oxidative destruction of the fatty membranes that surround cells. Ferroptosis has attracted intense interest in stroke research because the brain is exceptionally rich in lipids and vulnerable to lipid peroxidation, the chain reaction in which reactive oxygen species strip electrons from cell membranes until they rupture. When blood flow to part of the brain is interrupted, the resulting shortage of oxygen and glucose sets off several forms of cellular injury, and ferroptosis is thought to be one of the important contributors to the growing zone of dead and dying tissue known as the infarct.

The researchers began their investigation far from the living brain, in cell culture and in organotypic brain slices — thin sections of brain tissue kept alive in the laboratory. When the slices were deprived of oxygen and glucose, a standard experimental model of ischemic injury, treatment with ATM inhibitors protected neurons from cell death. AZD1390, the most clinically advanced of the compounds tested, reduced measurements associated with lipid peroxidation and dampened the induction of ferroptosis-associated transcripts, the molecular signatures that cells display when this particular death program is activated. In cultured MDA-MB-231 cells exposed to erastin, a chemical that reliably triggers ferroptosis, AZD1390 reduced lipid peroxidation in a dose-dependent manner, an effect quantified with C11-BODIPY staining and confirmed across six independent biological replicates with rigorous statistical testing.

With those cellular results in hand, the team moved to mouse models of ischemic stroke using permanent middle cerebral artery occlusion, a surgical technique that blocks one of the major arteries supplying the brain and closely mimics the vascular catastrophe of a human ischemic stroke. The outcome was striking — but only in some of the animals. When AZD1390 was given orally two hours after the vessel was occluded, infarct volume measured 72 hours later was reduced by 55.6 percent in B6/J mice and by 37.1 percent in B6/NJ mice compared with vehicle-treated controls. Yet in BALB mice, a strain with a different vascular makeup, the same drug at the same dose produced no significant reduction in infarct volume at all.

The explanation, the researchers found, lay in the anatomy of the brain’s collateral circulation. B6/J and B6/NJ mice possess relatively dense connections between their major cerebral arterial territories, meaning that when the middle cerebral artery is blocked, smaller vessels can still deliver blood to the threatened tissue from neighboring vascular territories. BALB mice have far fewer of these backup connections, leaving larger swaths of brain effectively cut off from any alternative blood supply. The pattern was reinforced in a second genetic experiment: mice lacking Rabep2, a gene associated with reduced collateral vessel density, showed no infarct reduction from oral AZD1390, while wild-type and heterozygous littermates with more intact collateral networks did benefit from the treatment.

To test whether restricted vascular access was truly the limiting factor, the researchers changed the delivery strategy. Instead of giving the drug orally and relying on the bloodstream to carry it into the damaged region, they applied AZD1390 directly to the exposed cortical surface just 15 minutes after stroke induction. Under those conditions, the drug’s protective effect reappeared even in the low-collateral animals: infarct volume fell by 28.8 percent in BALB mice and by 35.2 percent in Rabep2 knockout mice. The drug, in other words, was not intrinsically powerless in these animals — it simply could not reach the tissue it was meant to protect when the vascular routes into that tissue were sparse.

The implications reach well beyond a single experimental compound. Variation in collateral blood vessels is a well-recognized feature of human neuroanatomy, and patients differ substantially in how well their brains are equipped to withstand a major arterial blockage. If vascular access to threatened brain tissue is a key determinant of therapeutic response, as the Duke findings suggest, then collateral status could become an important stratification variable in preclinical research and, eventually, in clinical trials of therapies intended to reach ischemic tissue. Treatments that look disappointing when tested across an unselected population might prove highly effective in patients with robust collateral circulation, while patients with sparse collaterals might need alternative delivery strategies or combination approaches altogether.

The authors are careful, however, to delineate the limits of what their experiments establish. The study does not prove that collateral circulation alone explains the treatment response, because the topical and oral treatment experiments differed not only in delivery route but also in timing — the topical application came earlier, at 15 minutes rather than two hours, so the earlier intervention may itself have contributed to the apparent benefit. The molecular findings likewise require further testing: although the results are consistent with reduced ferroptosis-associated lipid oxidative injury, the measurements used are not specific enough to prove that ATM-dependent ferroptosis is the sole mechanism at work. The researchers note that direct ATM target-engagement studies, genetic experiments, ferroptosis-specific rescue studies, and analyses of oxidized phospholipids will all be needed to nail down the mechanism. The study also assessed infarct volume only at the 72-hour mark and did not measure neurological function, behavioral recovery, long-term outcomes, or safety.

AZD1390 itself is an investigational agent that has previously been studied for its ability to reach the brain in other clinical contexts, which made it an attractive candidate for a stroke application. But the present findings were obtained entirely in cells, brain slices, and mice, and they do not demonstrate safety or effectiveness for people with stroke. What the study does offer is a conceptual advance: a concrete, experimentally supported reason why the same stroke therapy can produce dramatically different results across biological settings. As researchers continue the long effort to translate laboratory neuroprotection into bedside benefit, the Duke team’s work adds collateral vascular anatomy to the list of factors that must be considered — a reminder that in the brain, the road a drug must travel to reach endangered neurons may matter as much as the drug’s molecular target. The work also underscores the value of genetically diverse animal models, since a treatment evaluated only in a single high-collateral strain might have appeared uniformly effective and masked the vascular dependency entirely.

Subject of Research: The role of collateral circulation in the protective effect of ATM inhibition against ferroptosis in experimental ischemic stroke

Article Title: Study links experimental stroke protection to the brain’s backup blood vessels

Article References: Study links experimental stroke protection to the brain’s backup blood vessels. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ischemic stroke, collateral circulation, AZD1390, ATM kinase, ferroptosis, lipid peroxidation, infarct volume, middle cerebral artery occlusion, Rabep2, neuroprotection, preclinical study, brain vasculature

Moyamoya vasculopathy is an umbrella term covering two related but distinct conditions. Moyamoya disease is a chronic, progressive narrowing of the terminal internal carotid arteries and the proximal segments of the anterior and middle cerebral arteries, accompanied by a hazy network of tiny collateral vessels at the base of the brain that resembles a puff of smoke on angiography, the meaning of the Japanese word moyamoya. Moyamoya syndrome, by contrast, produces a similar vascular picture but arises secondarily, most often when intracranial atherosclerosis mimics the appearance of the idiopathic disease. Distinguishing the two matters enormously, because their underlying biology, prognosis, and treatment strategies diverge, yet conventional angiography alone often cannot separate them reliably.

The research team, led by investigators at a major Chinese hospital registry, enrolled 398 consecutive adults with radiologically confirmed moyamoya vasculopathy between September 2017 and April 2025. Every patient underwent imaging on the same 3.0-Tesla MR scanner using a standardized protocol that included T1-weighted, T2-weighted, FLAIR, diffusion-weighted, and time-of-flight angiographic sequences, along with high-resolution vessel wall imaging. By scanning all participants on a single machine, the investigators eliminated the interscanner variability that often plagues multicenter imaging studies, allowing vessel wall measurements to be compared directly across the cohort.

High-resolution MRI has emerged in recent years as the decisive tool for separating the two etiologies. In moyamoya disease, the affected arteries typically show concentric, uniform wall thickening, a reduction in the outer diameter of the vessel, and negative or constrictive remodeling, meaning the artery wall shrinks inward as the disease progresses rather than expanding outward. Atherosclerosis-associated moyamoya vasculopathy displays the opposite signature: irregular, eccentric thickening caused by lipid-rich or hemorrhagic plaques, and positive or expansive remodeling, in which the vessel enlarges to accommodate plaque growth. Applying these criteria, the researchers classified 279 patients as having moyamoya disease and 61 as having the atherosclerosis-associated form.

The clinical profiles of the two groups differed in telling ways. Patients with moyamoya disease were more frequently female, consistent with the well-established female predominance of the idiopathic condition, and were significantly more likely to report a family history of early-onset stroke in first-degree relatives, a hallmark of the genetic predisposition linked to the RNF213 susceptibility gene. They also showed more frequent involvement of the posterior cerebral arteries, reflecting the diffuse, whole-circle-of-Willis nature of the disease. The atherosclerosis-associated group, though similar in age, lacked these familial and posterior-circulation signatures, reinforcing the view that it represents a secondary, plaque-driven process rather than a genetically driven arteriopathy.

To determine which imaging features actually tracked with stroke, the team took an unusually granular approach: they analyzed each cerebral hemisphere separately. Of the 558 hemispheres in the moyamoya disease group, 169 had suffered middle cerebral artery territory infarcts, visible as acute or chronic lesions on MRI, while 389 remained asymptomatic. Because the two hemispheres of the same patient are statistically correlated, the researchers used generalized estimating equations, a regression framework that treats each patient as a cluster, adjusting for age, sex, hypertension, diabetes, hyperlipidemia, smoking, alcohol use, and family history of early stroke. This design allowed each hemisphere to serve, in effect, as its own internal comparison.

The results in moyamoya disease were strikingly consistent. Ischemic hemispheres were independently associated with greater middle cerebral artery stenosis, more advanced Suzuki stage, and higher stenosis scores on the internal carotid, middle cerebral, and posterior cerebral arteries. The posterior cerebral artery score carried the strongest effect, with each one-point increase more than doubling the odds of ischemia. Intriguingly, the remodeling index of the middle cerebral artery showed the opposite relationship: hemispheres with more constrictive remodeling were more likely to be ischemic, suggesting that for a given degree of luminal narrowing, the inward shrinkage of the vessel wall compounds hemodynamic compromise, while better-preserved or compensating vessels maintain perfusion.

In the atherosclerosis-associated group, the picture inverted almost completely. Here, the degree of middle cerebral artery stenosis, the Suzuki stage, and the carotid and posterior circulation scores all lost their statistical significance after adjustment. What remained significant were the remodeling index of the middle cerebral artery, which was positively associated with ischemia, and involvement of the anterior cerebral artery. This pattern suggests that in plaque-driven moyamoya vasculopathy, it is not the raw percentage of narrowing that matters but how the vessel wall remodels around the plaque and whether the anterior circulation can still serve as a collateral pathway. Positive remodeling, long recognized as a marker of vulnerable atherosclerotic plaques, appears to signal danger rather than compensation in this group.

The authors are careful to frame these findings as cross-sectional associations rather than proven predictors of future stroke, noting that their definition of ischemic hemispheres included both acute and old infarcts, and that the retrospective, single-center design and the relatively small atherosclerotic subgroup impose limits on generalizability. They also acknowledge that a small fraction of patients lacked internal carotid artery involvement on angiography, a population that the revised 2022 diagnostic criteria would technically exclude, though sensitivity analyses excluding these patients left the results qualitatively unchanged. Even so, the hemisphere-level, cluster-adjusted analysis represents one of the most detailed noninvasive characterizations of moyamoya vasculopathy published to date.

The clinical implications are potentially far-reaching. For patients with moyamoya disease, quantitative measures such as stenosis severity, Suzuki stage, and combined arterial scores, together with evidence of constrictive remodeling, could help identify which hemisphere is at highest risk and guide the timing of revascularization surgery. For those with the atherosclerosis-associated form, attention should shift toward plaque behavior and anterior circulation collateral integrity rather than stenosis percentage alone, aligning management more closely with modern intracranial atherosclerosis care, where recent long-term evidence has questioned the value of stenting and pointed instead toward bypass options in selected cases. The study’s core lesson is that moyamoya vasculopathy is not one disease but two, and the artery wall itself, imaged at high resolution, tells clinicians which one they are treating.

Subject of Research: Etiology-specific associations between high-resolution MRI vessel wall features and cerebral infarction in adult moyamoya vasculopathy

Article Title: High‐Resolution MRI Revealed Different Etiology‐Specific Associations With Cerebral Infarction in Adult Moyamoya Vasculopathy

Article References: Han, G., Pan, J., Hong, Y., Fan, X., Yao, M., Zhou, L., Zhu, Y., Feng, F., & Ni, J. (2026). High‐Resolution MRI Revealed Different Etiology‐Specific Associations With Cerebral Infarction in Adult Moyamoya Vasculopathy. Annals of Clinical and Translational Neurology, 13(10), 2057-2067. https://doi.org/10.1002/acn3.70380

Image Credits: AI Generated

DOI: 10.1002/acn3.70380

Keywords: moyamoya disease, moyamoya vasculopathy, high-resolution MRI, vessel wall imaging, cerebral infarction, intracranial atherosclerosis, remodeling index, Suzuki stage, collateral circulation, stroke risk, RNF213, revascularization